title: Regulatory effects of deguelin on proliferation and cell cycle of Raji cells.
abstract: The underlying mechanism of deguelin regulating the cell cycle in human Burkitt's lymphoma cell line Raji cells in vitro, and the cytotoxicity of deguelin to Raji cells and human peripheral blood monocular cells (PBMCs) were investigated. The effects of deguelin on the growth of Raji cells were studied by 3-(4, 5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium (MTT) assay. Apoptosis was detected through Hoechst 33258 staining. The effect of deguelin on the cell cycle of Raji cells was studied by a propidium iodide method. The expression levels of cyclin D1, P21 and pRb were examined by using Western blotting. The results showed that the proliferation of Raji cells was inhibited in the deguelin-treated group, with a 24-h IC(50) value of 21.61 nmol/L and a 36-h IC(50) value of 17.07 nmol/L. Proliferation in Raji cells was inhibited significantly by deguelin, while little change was observed in PBMCs. Deguelin induced G(2)/M arrest in Raji cells. The expression of cyclin D1, P21 and pRb was dramatically down-regulated by deguelin in a dose-dependent manner. It was concluded that deguelin could inhibit the proliferation of Raji cells by arresting the cells at G(2)/M phase and inducing the cell apoptosis. Moreover, deguelin selectively induced apoptosis of Raji cells with low toxicity to PBMCs. The antitumor effects of deguelin were related to the down-regulated expression of cyclin D1, P21 and pRb proteins.
authors.affiliation: No. 457th Hospital of PLA, Wuhan, 430012, China.
authors.forename: Jin-Rong
authors.initials: JR
authors.lastname: Xiong
authors.affiliation: Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. whliuhongli@163.com.
authors.forename: Hong-Li
authors.initials: HL
authors.lastname: Liu
mesh_terms: D002453:Cell Cycle / Q000187:drug effects*; D002460:Cell Line; D049109:Cell Proliferation / Q000187:drug effects*; D006801:Humans; D012402:Rotenone / Q000031:analogs & derivatives* / Q000494:pharmacology
chemical_list: D012402:Rotenone; C107676:deguelin
references.citation: J Immunol Methods. 2002 Jul 1;265(1-2):73-80
references.pmid: 12072179
references.citation: Cancer Lett. 2013 May 10;332(1):102-9
references.pmid: 23348700
references.citation: J Cancer Res Clin Oncol. 2005 Jul;131(7):479-85
references.pmid: 15809880
references.citation: Int J Cancer. 2011 Dec 15;129(12):2916-27
references.pmid: 21472727
references.citation: Leuk Lymphoma. 2005 Nov;46(11):1569-73
references.pmid: 16236611
references.citation: Acta Pharmacol Sin. 2005 Jul;26(7):873-80
references.pmid: 15960896
references.citation: Toxicology. 2002 Dec 27;181-182:475-81
references.pmid: 12505356
references.citation: Cancer Chemother Pharmacol. 2001 Mar;47(3):263-8
references.pmid: 11320671
references.citation: Nature. 2001 May 17;411(6835):342-8
references.pmid: 11357141
references.citation: Apoptosis. 2004 Jul;9(4):437-47
references.pmid: 15192326
references.citation: Exp Biol Med (Maywood). 2004 Feb;229(2):163-9
references.pmid: 14734795
references.citation: Oncol Lett. 2012 Oct;4(4):677-681
references.pmid: 23226790
references.citation: Oncol Rep. 2012 Apr;27(4):959-64
references.pmid: 22227970
references.citation: J Natl Cancer Inst. 2003 Feb 19;95(4):291-302
references.pmid: 12591985
references.citation: Cancer Res. 1997 Aug 15;57(16):3424-8
references.pmid: 9270008
references.citation: Clin Cancer Res. 2004 Feb 1;10(3):1074-9
references.pmid: 14871987
references.citation: Br J Haematol. 2005 Jun;129(5):677-86
references.pmid: 15916691
references.citation: Acta Pharmacol Sin. 2005 Oct;26(10):1265-73
references.pmid: 16174445